American Joint Committee on Cancer Classification of Posterior Uveal Melanoma (Tumor Size Category) Predicts Prognosis in 7731 Patients

被引:105
作者
Shields, Carol L. [1 ]
Kaliki, Swathi [1 ]
Furuta, Minoru [1 ]
Fulco, Enzo [1 ]
Alarcon, Carolina [1 ]
Shields, Jerry A. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Inst, Ocular Oncol Serv, Philadelphia, PA 19107 USA
关键词
OUTCOMES;
D O I
10.1016/j.ophtha.2013.03.012
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the clinical features and prognosis of posterior uveal (ciliary body and choroid) melanoma based on the American Joint Committee on Cancer (AJCC) classification (7th edition) of primary tumor (T). Design: Retrospective, interventional case series. Participants: Seven thousand seven hundred thirty-one patients. Intervention: Ocular management including plaque radiotherapy, enucleation, local resection, or laser therapy. Main Outcome Measures: Melanoma-related metastasis and death. Results: Of 7731 patients with posterior uveal melanoma, the AJCC classification based on T was category T1 in 3557 (46%), T2 in 2082 (27%), T3 in 1599 (21%), and T4 in 493 (6%). Based on tumor categories T1, T2, T3, and T4, respectively, features that showed significant increase with tumor category included patient age at presentation (57, 58, 58, and 61 years; P<0.001), tumor base (8, 12, 15, and 20 mm; P<0.001), tumor thickness (3.5, 5.2, 8.9, and 11.4 mm; P<0.001), mushroom configuration (8%, 20%, 38%, and 39%; P<0.001), associated subretinal fluid (64%, 80%, 82%, and 83%; P<0.001), intraocular hemorrhage (5%, 12%, 17%, and 18%; P<0.001), rupture of Bruch's membrane (9%, 24%, 40%, and 40%; P<0.001), and extraocular extension (1%, <1%, 4%, and 12%; P<0.001). After therapy, Kaplan-Meier estimates of metastasis at 5, 10, and 20 years were 8%, 15%, and 25% for category T1, 14%, 25%, and 40% for category T2, 31%, 49%, and 62% for category T3, and 51%, 63%, and 69% for category T4, respectively (P<0.001). Kaplan-Meier estimates of death at 5, 10, and 20 years were 4%, 8%, and 11% for category T1, 8%, 13%, and 24% for category T2, 19%, 27%, and 36% for category T3, and 30%, 43%, and 51% for category T4, respectively (P<0.001). Compared with category T1, the hazard ratio for metastasis and death for T2 was 1.8 and 1.9, respectively, that for T3 was 4.5 and 4.7, respectively, and that for T4 was 8.2 and 8.8, respectively. Conclusions: Based on the AJCC classification, increasing tumor category was associated with older age, larger tumor, and greater incidence of subretinal fluid, hemorrhage, and extraocular extension. Compared with uveal melanoma classified as T1, the rate of metastasis and death was 2 times greater for T2, 4 times greater for T3, and 8 times greater for T4. The risk for metastasis and death increased 2-fold with each increasing melanoma category.
引用
收藏
页码:2066 / 2071
页数:6
相关论文
共 18 条
  • [1] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    Balch, CM
    Soong, SJ
    Gershenwald, JE
    Thompson, JF
    Reintgen, DS
    Cascinelli, N
    Urist, M
    McMasters, KM
    Ross, MI
    Kirkwood, JM
    Atkins, MB
    Thompson, JA
    Coit, DG
    Byrd, D
    Desmond, R
    Zhang, YT
    Liu, PY
    Lyman, GH
    Morabito, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3622 - 3634
  • [2] Collaborative Ocular Melanoma Grp, 2006, ARCH OPHTHALMOL-CHIC, V124, P1684
  • [3] Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification
    Damato, Bertil
    Dopierala, Justyna A.
    Coupland, Sarah E.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (24) : 6083 - 6092
  • [4] A REVIEW OF MORTALITY FROM CHOROIDAL MELANOMA .2. A METAANALYSIS OF 5-YEAR MORTALITY-RATES FOLLOWING ENUCLEATION, 1966 THROUGH 1988
    DIENERWEST, M
    HAWKINS, BS
    MARKOWITZ, JA
    SCHACHAT, AP
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (02) : 245 - 250
  • [5] Edge S.E., 2010, AJCC Cancer Staging Manual, V7th, P547
  • [6] Tumor doubling times in metastatic malignant melanoma of the uvea -: Tumor progression before and after treatment
    Eskelin, S
    Pyrhönen, S
    Summanen, P
    Hahka-Kemppinen, M
    Kivelä, T
    [J]. OPHTHALMOLOGY, 2000, 107 (08) : 1443 - 1449
  • [7] Molecular Prognostic Testing and Individualized Patient Care in Uveal Melanoma
    Harbour, J. William
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (06) : 823 - 829
  • [8] Clinical and Pathologic Characteristics of Biopsy-Proven Iris Melanoma A Multicenter International Study
    Khan, Samira
    Finger, Paul T.
    Yu, Guo-Pei
    Razzaq, Lubna
    Jager, Martine J.
    de Keizer, Rob J. W.
    Sandkull, Per
    Seregard, Stefan
    Gologorsky, Daniel
    Schefler, Amy C.
    Murray, Timothy G.
    Kivela, Tero
    Giuliari, Gian Paolo
    McGowan, Hugh
    Simpson, E. Rand
    Corriveau, Christine
    Coupland, Sarah E.
    Damato, Bertil E.
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (01) : 57 - 64
  • [9] Prescher G, 1996, LANCET, V347, P1222
  • [10] Interferon for Ocular Surface Squamous Neoplasia in 81 Cases: Outcomes Based on the American Joint Committee on Cancer Classification
    Shields, Carol L.
    Kaliki, Swathi
    Kim, H. Jane
    Al-Dahmash, Saad
    Shah, Sanket U.
    Lally, Sara E.
    Shields, Jerry A.
    [J]. CORNEA, 2013, 32 (03) : 248 - 256